For the treatment of AML, the HSP90 inhibitor NVP-AUY922 has shown synergistic anti-leukemic activity with Cytarabine in vivo19, and Ganetespib (STA-9090) has also been tested in combination with Cytarabine as a potential active agent20. Here, HSP90AB1 is linked to acute myeloid leukemia.